Vanda: Tiny Pharma, Big Opportunity?

The shares soared Thursday after a positive trial for a drug that could help the company crack the $10 billion schizophrenia market

Pharma investors have been waiting for some good news after recent negative headlines, including Pfizer's (PFE) termination of a clinical trial for a promising heart disease drug. The announcement fanned fears of a meager pipeline at the world's largest drug outfit. On Dec. 7, the favorable headline finally came, but it didn't emanate from Pfizer or any of its big-footed competitors. It came from tiny, unprofitable Vanda Pharmaceuticals (VNDA) of Rockville, Md.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.